ATE543497T1 - Substituierte heterozyklische derivate als mittel gegen diabetes und adipositas und verfahren - Google Patents

Substituierte heterozyklische derivate als mittel gegen diabetes und adipositas und verfahren

Info

Publication number: ATE543497T1
Authority: AT; Austria
Prior art keywords: obesity; methods; substituted heterocyclic; agent against; heterocyclic derivatives
Prior art date: 2002-07-09

Application number

AT03763345T

Other languages

English (en)

Inventor

Peter Cheng

Sean Chen

Charles Ding

Timothy Herpin

Original Assignee

Bristol Myers Squibb Co

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-07-09

Filing date

2003-07-08

Publication date

2012-02-15

2003-07-08 Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co

2012-02-15 Application granted granted Critical

2012-02-15 Publication of ATE543497T1 publication Critical patent/ATE543497T1/de

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
- C07D249/06—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles with aryl radicals directly attached to ring atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Diabetes (AREA)
Hematology (AREA)
Obesity (AREA)
Child & Adolescent Psychology (AREA)
Cardiology (AREA)
Endocrinology (AREA)
Vascular Medicine (AREA)
Emergency Medicine (AREA)
Heart & Thoracic Surgery (AREA)
Urology & Nephrology (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Dermatology (AREA)
Physical Education & Sports Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Plural Heterocyclic Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

AT03763345T 2002-07-09 2003-07-08 Substituierte heterozyklische derivate als mittel gegen diabetes und adipositas und verfahren ATE543497T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US39455302P	2002-07-09	2002-07-09
PCT/US2003/021331 WO2004004655A2 (en)	2002-07-09	2003-07-08	Substituted heterocyclic derivatives useful as antidiabetic and antiobesity agents and method

Publications (1)

Publication Number	Publication Date
ATE543497T1 true ATE543497T1 (de)	2012-02-15

Family

ID=30115733

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT03763345T ATE543497T1 (de)	2002-07-09	2003-07-08	Substituierte heterozyklische derivate als mittel gegen diabetes und adipositas und verfahren

Country Status (23)

Country	Link
US (2)	US6875782B2 (de)
EP (1)	EP1531810B1 (de)
JP (1)	JP4541883B2 (de)
KR (1)	KR101120337B1 (de)
CN (1)	CN1665500A (de)
AT (1)	ATE543497T1 (de)
AU (1)	AU2003248861B2 (de)
BR (1)	BR0312503A (de)
CA (1)	CA2490972C (de)
ES (1)	ES2380319T3 (de)
GE (1)	GEP20084475B (de)
HR (1)	HRP20050001A2 (de)
IL (1)	IL165809A (de)
IS (1)	IS7629A (de)
MX (1)	MXPA05000279A (de)
NO (1)	NO329328B1 (de)
NZ (1)	NZ537251A (de)
PL (1)	PL375230A1 (de)
RS (1)	RS20050002A (de)
RU (1)	RU2325381C2 (de)
UA (1)	UA79296C2 (de)
WO (1)	WO2004004655A2 (de)
ZA (1)	ZA200500029B (de)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE60316297T2 (de) *	2002-08-01	2008-06-19	Neurosearch A/S	Verbindungen, die zur behandlung von erkrankungen, die auf antiangiogene therapie ansprechen, nützlich sind
US20060183897A1 (en) *	2003-03-18	2006-08-17	Chakravarty Prasun K	Biaryl substituted triazoles as sodium channel blockers
AR044503A1 (es) *	2003-03-18	2005-09-14	Merck & Co Inc	Triazoles sustituidos con biarilo como bloqueantes del canal de sodio
US20040242566A1 (en)	2003-03-25	2004-12-02	Syrrx, Inc.	Dipeptidyl peptidase inhibitors
US7638638B2 (en)	2003-05-14	2009-12-29	Takeda San Diego, Inc.	Dipeptidyl peptidase inhibitors
ZA200602051B (en)	2003-08-13	2007-10-31	Takeda Pharmaceutical	4-pyrimidone derivatives and their use as peptidyl peptidase inhibitors
FR2861301B1 (fr) *	2003-10-24	2008-07-11	Sanofi Synthelabo	Utilisation du derive du pyrazole pour la preparation de medicaments utiles dans la prevention et le traitement du syndrome metabolique.
FR2861300B1 (fr) *	2003-10-24	2008-07-11	Sanofi Synthelabo	Utilisation d'un derive du pyrazole, pour la preparation de medicaments utiles dans la prevention et le traitement du syndrome metabolique
FR2861303A1 (fr) *	2003-10-24	2005-04-29	Sanofi Synthelabo	Utilisation d'un derive de pyrazole pour la preparation de medicaments utiles dans la prevention et le traitement du syndrome metabolique
FR2861302A1 (fr) *	2003-10-24	2005-04-29	Sanofi Synthelabo	Utilisation d'un derive du pyrazole, pour la preparation de medicaments utiles dans la prevention et le traitement du syndrome metabolique.
US7829552B2 (en) *	2003-11-19	2010-11-09	Metabasis Therapeutics, Inc.	Phosphorus-containing thyromimetics
SI1725234T1 (sl)	2004-03-05	2013-04-30	The Trustees Of The University Of Pennsylvania	Postopki zdravljenja nepravilnosti ali bolezni povezanih s hiperlipidemijo in hiperholesterolemijo z minimiziranjem stranskih uäśinkov
WO2005115384A2 (en) *	2004-05-25	2005-12-08	Metabolex, Inc.	Bicyclic, substituted triazoles as modulators of ppar and methods of their preparation
ZA200610650B (en) *	2004-05-25	2009-04-29	Metabolex Inc	Substituted triazoles as modulators of PPAR and methods of their preparation
US20060058224A1 (en) *	2004-09-15	2006-03-16	Yancopoulos George D	Methods of treating obesity with combination therapeutics
MX2007003732A (es) *	2004-09-29	2007-04-23	Schering Corp	Combinaciones de azetidononas sustituidas y antagonistas de receptor de canabinoide 1.
JP5140577B2 (ja) *	2005-03-31	2013-02-06	タケダカリフォルニアインコーポレイテッド	ヒドロキシステロイドデヒドロゲナーゼ阻害剤
WO2006117743A1 (en) *	2005-05-03	2006-11-09	Ranbaxy Laboratories Limited	Substituted aromatic compounds as antidiabetic agents
EP1890768A2 (de) *	2005-05-26	2008-02-27	Metabasis Therapeutics, Inc.	Neue phosphinsäurehaltige thyromimetika
JP2008542301A (ja)	2005-05-26	2008-11-27	メタバシス・セラピューティクス・インコーポレイテッド	脂肪性肝疾患の処置のための甲状腺ホルモン様薬剤
FR2889191A1 (fr) *	2005-07-28	2007-02-02	Cerep Sa	Composes derives de 5-benzylidene imidazolidine 2,4-dione et leur utilisation en tant qu'antagonistes de mchr-1
PE20070522A1 (es)	2005-09-14	2007-07-11	Takeda Pharmaceutical	2-[6-(3-amino-piperidin-1-il)-3-metil-2,4-dioxo-3,4-dihidro-2h-pirimidin-1-ilmetil]-4-fluoro-benzonitrilo como inhibidor de dipeptidil peptidasa y composiciones farmaceuticas que lo contienen
CA2622642C (en)	2005-09-16	2013-12-31	Takeda Pharmaceutical Company Limited	Dipeptidyl peptidase inhibitors
US20070088089A1 (en) *	2005-10-18	2007-04-19	Wisler Gerald L	Methods for treating disorders associated with hyperlipidemia in a mammal
NZ572585A (en) *	2006-05-30	2011-02-25	Astrazeneca Ab	1,3,4-Oxadiazole derivatives as DGAT1 inhibitors
US8084478B2 (en) *	2006-05-30	2011-12-27	Asstrazeneca Ab	Substituted 5- phenylamino- 1, 3, 4-oxadiazol-2-ylcarbonylamino-4-phenoxy-cyclohexane carboxylic acid as inhibitors of acetyl coenzyme A diacylglycerol acyltransferase
US20080009534A1 (en) *	2006-07-07	2008-01-10	Bristol-Myers Squibb Company	Substituted acid derivatives useful as antidiabetic and antiobesity agents and method
US8324383B2 (en)	2006-09-13	2012-12-04	Takeda Pharmaceutical Company Limited	Methods of making polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile
US8217025B2 (en) *	2006-11-17	2012-07-10	Harbor Therapeutics, Inc.	Drug screening and treatment methods
TW200838536A (en)	2006-11-29	2008-10-01	Takeda Pharmaceutical	Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor
CA2673290A1 (en) *	2006-12-21	2008-07-03	Aegerion Pharmaceuticals, Inc.	Methods for treating obesity with a combination comprising a mtp inhibitor and a cholesterol absorption inhibitor
US8093236B2 (en)	2007-03-13	2012-01-10	Takeda Pharmaceuticals Company Limited	Weekly administration of dipeptidyl peptidase inhibitors
TW200906823A (en)	2007-07-16	2009-02-16	Lilly Co Eli	Compounds and methods for modulating FXR
US8652527B1 (en)	2013-03-13	2014-02-18	Upsher-Smith Laboratories, Inc	Extended-release topiramate capsules
US9101545B2 (en)	2013-03-15	2015-08-11	Upsher-Smith Laboratories, Inc.	Extended-release topiramate capsules
CN103694195B (zh) *	2013-09-18	2016-04-06	华东师范大学	芳香杂环类小分子有机化合物及衍生物、制备方法及医药用途
EP3190103A1 (de) *	2016-01-08	2017-07-12	Rijksuniversiteit Groningen	Inhibitoren der pd-1/pd-l1-protein-/proteinwechselwirkung
BR112019010249A2 (pt)	2016-11-21	2019-09-10	Viking Therapeutics Inc	método de tratamento de doença de armazenamento de glicogênio
AU2018280118B2 (en)	2017-06-05	2021-07-15	Viking Therapeutics, Inc.	Compositions for the treatment of fibrosis
KR101943382B1 (ko)	2017-09-19	2019-01-29	오토텔릭바이오 주식회사	Sglt-2 저해제 및 안지오텐신 수용체 차단제를 포함하는 의약 조성물
AU2019238090B2 (en)	2018-03-22	2024-08-01	Viking Therapeutics, Inc.	Crystalline forms and methods of producing crystalline forms of a compound
KR102131359B1 (ko) *	2018-09-07	2020-07-07	오토텔릭바이오 주식회사	안정성이 향상된 의약 조성물
US12102646B2 (en)	2018-12-05	2024-10-01	Viking Therapeutics, Inc.	Compositions for the treatment of fibrosis and inflammation

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ES2156933T3 (es)	1993-12-28	2001-08-01	Meiji Seika Co	Derivados triciclicos de benzazepina y benzotiazepina.
JPH10501222A (ja) *	1994-05-27	1998-02-03	メルクエンドカンパニーインコーポレーテッド	破骨細胞仲介骨吸収を抑制するための化合物
WO1997000258A1 (fr)	1995-06-15	1997-01-03	Meiji Seika Kabushiki Kaisha	Composes de benzazepine tricyclique
GB9604242D0 (en) *	1996-02-28	1996-05-01	Glaxo Wellcome Inc	Chemical compounds
JP3215048B2 (ja) *	1996-04-03	2001-10-02	日本たばこ産業株式会社	プロピオン酸誘導体及びその用途
JPH1067759A (ja)	1996-06-20	1998-03-10	Sankyo Co Ltd	除草性アゾール誘導体
JPH11263775A (ja)	1997-09-08	1999-09-28	Sankyo Co Ltd	ヒドロキシアニリン誘導体
DE69811930T2 (de)	1997-09-29	2003-12-18	Meiji Seika Kaisha Ltd., Tokio/Tokyo	Tricyclische triazolobenzazepinderivate, verfahren zu ihrer herstellung und antiallergische mittel
DE69941777D1 (de) *	1998-03-10	2010-01-21	Ono Pharmaceutical Co	Carbonsäurederivate und medikamente die diese als aktiven wirkstoff enthalten
FR2778314B1 (fr)	1998-05-07	2002-06-14	Rhone Poulenc Agrochimie	Composition fongicide synergique comprenant un compose analogue de la strobilurine
GB9914977D0 (en) *	1999-06-25	1999-08-25	Glaxo Group Ltd	Chemical compounds
AU7115300A (en) *	1999-09-08	2001-04-10	Glaxo Group Limited	Oxazole ppar antagonists
US6414002B1 (en) *	1999-09-22	2002-07-02	Bristol-Myers Squibb Company	Substituted acid derivatives useful as antidiabetic and antiobesity agents and method
TWI302149B (en) *	1999-09-22	2008-10-21	Bristol Myers Squibb Co	Substituted acid derivatives useful as antiodiabetic and antiobesity agents and method
CZ20021604A3 (cs)	1999-11-10	2002-09-11	Takeda Chemical Industries, Ltd.	Pětičlenné N-heterocyklické sloučeniny, farmaceutický přípravek a činidlo je obsahující a jejich použití
GB0029974D0 (en) *	2000-12-08	2001-01-24	Glaxo Group Ltd	Chemical compounds

2003
- 2003-07-08 CA CA2490972A patent/CA2490972C/en not_active Expired - Fee Related
- 2003-07-08 RU RU2005103395/04A patent/RU2325381C2/ru not_active IP Right Cessation
- 2003-07-08 GE GEAP8617A patent/GEP20084475B/en unknown
- 2003-07-08 US US10/616,283 patent/US6875782B2/en not_active Expired - Lifetime
- 2003-07-08 WO PCT/US2003/021331 patent/WO2004004655A2/en active Application Filing
- 2003-07-08 AT AT03763345T patent/ATE543497T1/de active
- 2003-07-08 CN CN038160382A patent/CN1665500A/zh active Pending
- 2003-07-08 KR KR1020057000362A patent/KR101120337B1/ko not_active IP Right Cessation
- 2003-07-08 JP JP2004520018A patent/JP4541883B2/ja not_active Expired - Fee Related
- 2003-07-08 NZ NZ537251A patent/NZ537251A/en not_active IP Right Cessation
- 2003-07-08 MX MXPA05000279A patent/MXPA05000279A/es active IP Right Grant
- 2003-07-08 RS YUP-2005/0002A patent/RS20050002A/sr unknown
- 2003-07-08 AU AU2003248861A patent/AU2003248861B2/en not_active Ceased
- 2003-07-08 PL PL03375230A patent/PL375230A1/xx not_active Application Discontinuation
- 2003-07-08 ES ES03763345T patent/ES2380319T3/es not_active Expired - Lifetime
- 2003-07-08 EP EP03763345A patent/EP1531810B1/de not_active Expired - Lifetime
- 2003-07-08 BR BRPI0312503-3A patent/BR0312503A/pt not_active IP Right Cessation
- 2003-08-07 UA UAA200501187A patent/UA79296C2/uk unknown
2004
- 2004-12-16 IL IL165809A patent/IL165809A/en not_active IP Right Cessation
- 2004-12-17 NO NO20045529A patent/NO329328B1/no not_active IP Right Cessation
- 2004-12-17 US US11/016,183 patent/US7507757B2/en not_active Expired - Lifetime
2005
- 2005-01-03 ZA ZA200500029A patent/ZA200500029B/xx unknown
- 2005-01-04 HR HR20050001A patent/HRP20050001A2/hr not_active Application Discontinuation
- 2005-01-05 IS IS7629A patent/IS7629A/is unknown

Also Published As

Publication number	Publication date
NO329328B1 (no)	2010-09-27
MXPA05000279A (es)	2005-03-31
PL375230A1 (en)	2005-11-28
EP1531810B1 (de)	2012-02-01
US20040063762A1 (en)	2004-04-01
CA2490972C (en)	2012-05-29
KR101120337B1 (ko)	2012-02-29
JP4541883B2 (ja)	2010-09-08
IL165809A0 (en)	2006-01-15
HRP20050001A2 (en)	2005-08-31
EP1531810A2 (de)	2005-05-25
EP1531810A4 (de)	2008-05-28
US20050119312A1 (en)	2005-06-02
JP2006501187A (ja)	2006-01-12
KR20050025951A (ko)	2005-03-14
NO20045529L (no)	2005-02-03
RU2325381C2 (ru)	2008-05-27
CN1665500A (zh)	2005-09-07
UA79296C2 (en)	2007-06-11
IS7629A (is)	2005-01-05
RU2005103395A (ru)	2005-08-10
RS20050002A (en)	2007-09-21
BR0312503A (pt)	2007-06-26
GEP20084475B (en)	2008-09-10
US6875782B2 (en)	2005-04-05
AU2003248861B2 (en)	2009-01-22
AU2003248861A1 (en)	2004-01-23
WO2004004655A2 (en)	2004-01-15
WO2004004655A3 (en)	2004-10-14
ZA200500029B (en)	2006-06-28
ES2380319T3 (es)	2012-05-10
NZ537251A (en)	2007-02-23
US7507757B2 (en)	2009-03-24
CA2490972A1 (en)	2004-01-15
IL165809A (en)	2010-05-17

Publication	Publication Date	Title
ATE543497T1 (de)	2012-02-15	Substituierte heterozyklische derivate als mittel gegen diabetes und adipositas und verfahren
ECSP055813A (es)	2005-08-11	Quinolin-, isoquinolin- y quinazolin-oxialquilamidas y su uso como fungicidas
ATE447404T1 (de)	2009-11-15	Substituierte benzazole und ihre verwendung als raf-kinase-hemmer
DE60308210D1 (de)	2006-10-19	Medizinische fassvorrichtung
BRPI0417717A (pt)	2007-04-03	composto, composição farmacêutica, e, uso de um composto
CY2014001I1 (el)	2014-07-02	Συνδυασμος αζελαστινης και φλουτικαζονης
DK1620437T3 (da)	2009-08-24	5,7-diaminopyrazolo-4,3-d-pyrimidiner, der er anvendelige til behandling af hypertension
CY1111867T1 (el)	2015-11-04	Ενωση ενεργοποιησης ppar και φαρμακευτικη συνθεση που περιεχει αυτη
WO2004004665A3 (en)	2004-03-25	Substituted heterocyclic derivatives useful as antidiabetic and antiobesity agents and method
CY1114284T1 (el)	2016-08-31	Σουλφονυλοπυρρολες ως hdac αναστολεις
CY1107156T1 (el)	2012-10-24	Νεα μεθοδος συνθεσης του (7-μεθοξυ-3,4-διυδρο-1-ναφθαλινυλ) ακετονιτριλιου και εφαρμογη στη συνθεση της αγομελατινης
BRPI0417858A (pt)	2007-04-27	composto, composição farmacêutica, e, uso de uma composição farmacêutica
EA200800681A1 (ru)	2008-10-30	Применение киралаксила для защиты от фитопатогенов и соответствующие способы и композиции
ECSP044971A (es)	2004-03-23	Isoxazolopiridinonas y su uso en el tratamiento de enfermedad de parkinson
DE60321641D1 (de)	2008-07-31	Photopolymerisierbare Initiatorkombination und photopolymerisierbare Zusammensetzung
ATE371662T1 (de)	2007-09-15	Siliziumverbindungen und deren verwendung
BRPI0500536A (pt)	2005-12-06	Composição antimicrobiana
BR0316544A (pt)	2005-10-04	Compostos calcilìticos
ATE484503T1 (de)	2010-10-15	2-pyrrolidin-2-yl-ä1,3,4ü -oxadiazol-derivate und ihre verwendung als antidepressiva
DE60307997D1 (de)	2006-10-12	Zusammensetzungen mit biostimulierender wirksamkeit
ATE456568T1 (de)	2010-02-15	Kondensierte heterocyclische isoxazolinderivate und deren verwendung als antidepressiva
ATE374778T1 (de)	2007-10-15	Organosiliziumverbindungen und deren verwendung
ECSP056174A (es)	2006-04-19	Acidos hidroxamicos utiles en el tratamiento detrastornos hiperproliferativos
ATE273302T1 (de)	2004-08-15	Diazocinderivate und deren verwendung als tryptase inhibitoren
NO20070058L (no)	2007-01-05	Amino-halogen-imidazopyridiner som protonpumpeinhibitorer